Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-20260416-133111",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"H3_PARP1_NAD_depletion\",\n      \"hypothesis_name\": \"PARP1 Hyperactivation as NAD+-Depleting Driver of NAMPT Dysfunction\",\n      \"target\": \"PARP1\",\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.72,\n        \"evidence_strength\": 0.68,\n        \"novelty\": 0.50,\n        \"feasibility\": 0.80,\n        \"therapeutic_potential\": 0.75,\n        \"druggability\": 0.88,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.80,\n        \"data_availability\": 0.72,\n        \"reproducibility\": 0.78\n      },\n      \"composite_score\": 6.18,\n      \"confidence_initial\": 0.58,\n      \"confidence_skeptic\": 0.39,\n      \"confidence_expert\": null,\n      \"final_confidence\": 0.55,\n      \"evidence_for\": [\n        {\"claim\": \"PARP1 activation depletes cellular NAD+ pools in excitotoxicity models\", \"pmid\": \"12401704\"},\n        {\"claim\": \"PARP1 knockout mice show preserved NAD+ levels and mitochondrial function with age\", \"pmid\": \"17612497\"},\n        {\"claim\": \"NAMPT activity inversely correlates with PARP activation in AD brain tissue\", \"pmid\": \"31171699\"},\n        {\"claim\": \"CD38 is actually the larger NAD+ consumer in aging immune cells\", \"pmid\": \"30241982\"},\n        {\"claim\": \"Multiple FDA-approved PARP inhibitors exist with well-characterized pharmacology\", \"pmid\": null}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PARP1 has normal neuronal functions in DNA repair, memory-related transcriptional responses, and sleep-linked genome maintenance\", \"pmid\": \"34798058\"},\n        {\"claim\": \"Impaired PARP1 can itself cause genome instability\", \"pmid\": \"37487079\"},\n        {\"claim\": \"CD38 is the larger NAD+ consumer in aging immune cells, so PARP1 inhibition alone may be insufficient\", \"pmid\": \"30241982\"}\n      ],\n      \"key_uncertainties\": [\n        \"Whether PARP1 inhibition specifically in microglia vs neurons is required\",\n        \"Optimal dosing to preserve DNA repair while blocking NAD+ depletion\",\n        \"Whether CD38 compensation undermines PARP1 monotherapy\"\n      ],\n      \"recommended_experiments\": [\n        \"Test niraparib (best CNS penetration) at sub-toxic doses in AD models\",\n        \"Quantify microglial-specific NAD+, NAMPT flux, and SASP biomarkers\",\n        \"Separate PARP1 from CD38 contributions using genetic models\",\n        \"Develop CNS-optimized PARP1 inhibitor if preclinical data supports\"\n      ]\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"H6_Complement_C3_redirect\",\n      \"hypothesis_name\": \"C1q-Independent but C3-Redirecting Complement Therapy to Protect PV Basket Cell Synapses\",\n      \"target\": \"C3/CR3\",\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.75,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.65,\n        \"data_availability\": 0.58,\n        \"reproducibility\": 0.65\n      },\n      \"composite_score\": 5.90,\n      \"confidence_initial\": 0.53,\n      \"confidence_skeptic\": 0.31,\n      \"confidence_expert\": null,\n      \"final_confidence\": 0.48,\n      \"evidence_for\": [\n        {\"claim\": \"C1q/C3-dependent synaptic pruning occurs in AD mouse models\", \"pmid\": \"28602351\"},\n        {\"claim\": \"PV interneuron perisomatic synapses show selective complement deposition in 5xFAD mice\", \"pmid\": \"30643258\"},\n        {\"claim\": \"Anti-C1q antibodies prevent synapse loss\", \"pmid\": \"31009446\"},\n        {\"claim\": \"Multiple complement-targeting biologics are FDA-approved or in development\", \"pmid\": null}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"C3 deficiency can accelerate amyloid deposition and neurodegeneration\", \"pmid\": \"18562603\"},\n        {\"claim\": \"C3 loss in later-stage APP/PS1 mice preserves synapses but worsens amyloid\", \"pmid\": \"28566429\"},\n        {\"claim\": \"Complement-mediated injury may also extend through MAC, not just C3 opsonization\", \"pmid\": \"35794654\"},\n        {\"claim\": \"PV synapse loss may be driven by microglial activation, perineuronal-net degradation, or activity-dependent remodeling\", \"pmid\": \"32745992\"}\n      ],\n      \"key_uncertainties\": [\n        \"Stage-dependency: complement pruning vs plaque clearance roles\",\n        \"BBB penetration of anti-C3 antibodies\",\n        \"Whether redirecting C3 (vs blocking) is mechanistically achievable\",\n        \"Infection risk from complement inhibition\"\n      ],\n      \"recommended_experiments\": [\n        \"Stage-specific C3 inhibition in early vs late AD models\",\n        \"Test CNS-penetrant anti-C3 or C3a receptor agonist\",\n        \"Quantify PV perisomatic synapses, plaque burden, and infection susceptibility simultaneously\",\n        \"Compare C1q vs C3 vs MAC inhibition approaches\"\n      ]\n    },\n    {\n      \"rank\": 3,\n      \"hypothesis_id\": \"H2_LDHB_lactate_oxidation\",\n      \"hypothesis_name\": \"LDHB Isoform Switching to Drive Lactate Oxidation in PV Interneurons\",\n      \"target\": \"LDHB\",\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.42,\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.68,\n        \"feasibility\": 0.35,\n        \"therapeutic_potential\": 0.48,\n        \"druggability\": 0.40,\n        \"safety_profile\": 0.65,\n        \"competitive_landscape\": 0.75,\n        \"data_availability\": 0.45,\n        \"reproducibility\": 0.50\n      },\n      \"composite_score\": 5.18,\n      \"confidence_initial\": 0.52,\n      \"confidence_skeptic\": 0.22,\n      \"confidence_expert\": null,\n      \"final_confidence\": 0.38,\n      \"evidence_for\": [\n        {\"claim\": \"Human PV basket cells show enriched LDHB expression for aerobic lactate utilization\", \"pmid\": \"28602351\"},\n        {\"claim\": \"Ketogenic diet increases LDHB expression in hippocampus\", \"pmid\": \"29396894\"},\n        {\"claim\": \"LDH-B subunit shift toward oxidative metabolism is observed in fast-spiking neurons\", \"pmid\": \"26354854\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Neuronal activity has been reported to correlate better with glucose than lactate utilization\", \"pmid\": \"19393013\"},\n        {\"claim\": \"Energetic centrality of the astrocyte-neuron lactate shuttle remains explicitly contested\", \"pmid\": \"28151548\"},\n        {\"claim\": \"LDHB loss impairs long-term memory but phenotype is not PV-specific and neuropathology is mild\", \"pmid\": \"39566837\"}\n      ],\n      \"key_uncertainties\": [\n        \"Whether lactate shuttle is the dominant metabolic pathway in adult PV neurons\",\n        \"Whether LDHB is rate-limiting vs other metabolic bottlenecks\",\n        \"Feasibility of developing LDHB activators\"\n      ],\n      \"recommended_experiments\": [\n        \"PV-cell-specific LDHB overexpression with 13C-lactate vs 13C-glucose flux tracing\",\n        \"Patch-clamp and gamma-oscillation rescue in AD models\",\n        \"Test whether metabolic rescue requires LDHB vs glucose utilization pathways\"\n      ]\n    },\n    {\n      \"rank\": 4,\n      \"hypothesis_id\": \"H1_ID2_PV_repression\",\n      \"hypothesis_name\": \"ID2-Mediated PV Repression as a Convergence Point for Metabolic and Transcriptional Dysfunction\",\n      \"target\": \"ID2\",\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.38,\n        \"evidence_strength\": 0.38,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.22,\n        \"therapeutic_potential\": 0.50,\n        \"druggability\": 0.18,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.85,\n        \"data_availability\": 0.28,\n        \"reproducibility\": 0.40\n      },\n      \"composite_score\": 4.49,\n      \"confidence_initial\": 0.55,\n      \"confidence_skeptic\": 0.27,\n      \"confidence_expert\": null,\n      \"final_confidence\": 0.35,\n      \"evidence_for\": [\n        {\"claim\": \"ID2 overexpression in GABAergic progenitors redirects them toward non-PV fates\", \"pmid\": \"19796621\"},\n        {\"claim\": \"ID proteins interact with PGC-1α to suppress mitochondrial biogenesis\", \"pmid\": \"15684424\"},\n        {\"claim\": \"ID2 is significantly upregulated in AD prefrontal cortex\", \"pmid\": \"29668080\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"PGC-1α itself is reduced in AD brain but ID2 has not been identified as upstream cause\", \"pmid\": \"19273754\"},\n        {\"claim\": \"APP/AICD signaling can increase PGC-1α expression, arguing against simple monotonic repression\", \"pmid\": \"24304563\"},\n        {\"claim\": \"Early AD models can show PV interneuron hyperactivity, not just PV loss/silencing\", \"pmid\": \"40913114\"},\n        {\"claim\": \"No single-cell ID2 measurement in human AD PV interneurons exists\", \"pmid\": null}\n      ],\n      \"key_uncertainties\": [\n        \"Cell-type specificity: adult PV dysfunction in AD not shown to be driven by ID2 in vivo\",\n        \"Lack of selective ID2 inhibitors or chemical probes\",\n        \"Whether developmental ID2 mechanisms translate to adult brain\"\n      ],\n      \"recommended_experiments\": [\n        \"snRNA-seq/snATAC to measure ID2 specifically in PV neurons from human AD tissue\",\n        \"CRISPRi/knockdown ID2 only in adult PV cells\",\n        \"Test whether PV markers, firing, and mitochondrial respiration recover independently of amyloid\"\n      ]\n    },\n    {\n      \"rank\": 5,\n      \"hypothesis_id\": \"H4_MCT1_lactate_shuttle\",\n      \"hypothesis_name\": \"MCT1-Mediated Astrocyte-to-PV Interneuron Lactate Shuttle Impairment in AD\",\n      \"target\": \"MCT1/SLC16A1\",\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.40,\n        \"evidence_strength\": 0.42,\n        \"novelty\": 0.62,\n        \"feasibility\": 0.28,\n        \"therapeutic_potential\": 0.45,\n        \"druggability\": 0.35,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.45\n      },\n      \"composite_score\": 4.62,\n      \"confidence_initial\": 0.50,\n      \"confidence_skeptic\": 0.25,\n      \"confidence_expert\": null,\n      \"final_confidence\": 0.33,\n      \"evidence_for\": [\n        {\"claim\": \"MCT1 is predominantly astrocytic and essential for lactate efflux\", \"pmid\": \"20870729\"},\n        {\"claim\": \"Conditional MCT1 knockout in astrocytes causes neuronal hypometabolism\", \"pmid\": \"23904267\"},\n        {\"claim\": \"Astrocytic metabolic dysfunction is an early AD feature\", \"pmid\": \"28867487\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"CNS MCT1 is strongly expressed in oligodendroglia and required for axonal support\", \"pmid\": \"22801498\"},\n        {\"claim\": \"In adult human cortex, MCT1 is also abundant in blood vessels and astrocytes\", \"pmid\": \"16403470\"},\n        {\"claim\": \"AD lactate-handling defects may be dominated by endothelial transport, oligodendrocyte support, or neuronal MCT2\", \"pmid\": null}\n      ],\n      \"key_uncertainties\": [\n        \"Cell-type specificity flaw: MCT1 is not uniquely astrocytic\",\n        \"No selective MCT1 activators exist\",\n        \"Gene therapy approach (AAV-GFAP-MCT1) faces delivery challenges\"\n      ],\n      \"recommended_experiments\": [\n        \"Astrocyte-specific vs oligodendrocyte-specific MCT1 rescue in AD models\",\n        \"Measure PV-cell lactate uptake, firing, and gamma rhythms\",\n        \"If astrocyte-only rescue fails while oligodendrocyte rescue works, proposed mechanism is wrong\"\n      ]\n    },\n    {\n      \"rank\": 6,\n      \"hypothesis_id\": \"H7_xCT_antiporter\",\n      \"hypothesis_name\": \"Astrocytic Cysteine-Glutamate Antiporter (xCT/SLC7A11) Dysfunction in PV Interneuron Excitation-Inhibition Imbalance\",\n      \"target\": \"SLC7A11\",\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.32,\n        \"evidence_strength\": 0.35,\n        \"novelty\": 0.58,\n        \"feasibility\": 0.38,\n        \"therapeutic_potential\": 0.38,\n        \"druggability\": 0.28,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.65,\n        \"data_availability\": 0.32,\n        \"reproducibility\": 0.42\n      },\n      \"composite_score\": 4.23,\n      \"confidence_initial\": 0.46,\n      \"confidence_skeptic\": 0.20,\n      \"confidence_expert\": null,\n      \"final_confidence\": 0.30,\n      \"evidence_for\": [\n        {\"claim\": \"xCT expression declines in AD brain and correlates with oxidative stress markers\", \"pmid\": \"25280565\"},\n        {\"claim\": \"System xc- inhibition preferentially affects GABAergic interneurons due to high firing rates\", \"pmid\": \"22159099\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Microglial/system xc- activity can itself mediate glutamate-dependent neurotoxicity\", \"pmid\": \"17475885\"},\n        {\"claim\": \"Sulfasalazine neuroprotective effects are more likely from NMDA-receptor antagonism, not xCT inhibition\", \"pmid\": \"12649352\"},\n        {\"claim\": \"xCT activation increases extracellular glutamate export, contradicting excitotoxicity reduction logic\", \"pmid\": null}\n      ],\n      \"key_uncertainties\": [\n        \"Internal contradiction: xCT activation simultaneously increases glutamate release\",\n        \"Sulfasalazine effects cannot be attributed to xCT\",\n        \"Whether oxidative stress in PV cells comes more from mitochondrial ROS vs xCT deficiency\"\n      ],\n      \"recommended_experiments\": [\n        \"Cell-type-specific xCT manipulation in astrocytes vs microglia\",\n        \"Simultaneous measures of extracellular glutamate, glutathione, PV firing, and survival\",\n        \"If astrocytic xCT activation improves GSH but worsens glutamate stress, hypothesis fails\"\n      ]\n    },\n    {\n      \"rank\": 7,\n      \"hypothesis_id\": \"H5_ERRa_agonism\",\n      \"hypothesis_name\": \"ERRα Agonism to Drive Mitochondrial Biogenesis Specifically in GABAergic Interneurons\",\n      \"target\": \"ESRRA\",\n      \"scores\": {\n        \"mechanistic_plausibility\": 0.28,\n        \"evidence_strength\": 0.25,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.18,\n        \"therapeutic_potential\": 0.40,\n        \"druggability\": 0.12,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.90,\n        \"data_availability\": 0.22,\n        \"reproducibility\": 0.35\n      },\n      \"composite_score\": 3.90,\n      \"confidence_initial\": 0.48,\n      \"confidence_skeptic\": 0.18,\n      \"confidence_expert\": null,\n      \"final_confidence\": 0.22,\n      \"evidence_for\": [\n        {\"claim\": \"ERRα regulates genes involved in mitochondrial function and lactate metabolism\", \"pmid\": \"10823931\"},\n        {\"claim\": \"PGC-1α coactivates ERRα for mitochondrial biogenesis in high-energy-demand neurons\", \"pmid\": \"14651853\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"GSK4716 is an ERRβ/γ agonist, not ERRα agonist - critical pharmacological error\", \"pmid\": \"32173553\"},\n        {\"claim\": \"ERR field lacks effective selective chemical tools for ERRα agonism\", \"pmid\": \"32683181\"},\n        {\"claim\": \"No ERRα-selective chemical probes exist for target engagement studies\", \"pmid\": null}\n      ],\n      \"key_uncertainties\": [\n        \"No selective ERRα agonists exist\",\n        \"Cited compound GSK4716 is ERRβ/γ agonist, not ERRα\",\n        \"PV vulnerability may reflect ion-channel defects more than insufficient ERRα-mediated biogenesis\"\n      ],\n      \"recommended_experiments\": [\n        \"Establish validated ERRα-selective agonist or PV-specific ESRRA overexpression first\",\n        \"Prove target engagement before therapeutic testing\",\n        \"If rescue requires ERRγ or broad metabolic changes, ERRα hypothesis collapses\"\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source\": \"ID2\",\n      \"target\": \"PVALB\",\n      \"relationship\": \"represses_transcription\",\n      \"pmid\": \"19796621\",\n      \"context\": \"Developmental GABAergic progenitor fate specification\"\n    },\n    {\n      \"source\": \"ID2\",\n      \"target\": \"PGC-1α\",\n      \"relationship\": \"inhibits_interaction\",\n      \"pmid\": \"15684424\",\n      \"context\": \"ID proteins suppress mitochondrial biogenesis through PGC-1α binding\"\n    },\n    {\n      \"source\": \"APP/AICD\",\n      \"target\": \"PGC-1α\",\n      \"relationship\": \"can_increase_expression\",\n      \"pmid\": \"24304563\",\n      \"context\": \"Complicates simple ID2→PGC-1α repression model\"\n    },\n    {\n      \"source\": \"PARP1\",\n      \"target\": \"NAD+\",\n      \"relationship\": \"consumes_pool\",\n      \"pmid\": \"12401704\",\n      \"context\": \"Hyperactivation depletes cellular NAD+\"\n    },\n    {\n      \"source\": \"PARP1\",\n      \"target\": \"NAMPT\",\n      \"relationship\": \"inversely_correlates_activity\",\n      \"pmid\": \"31171699\",\n      \"context\": \"In AD brain tissue\"\n    },\n    {\n      \"source\": \"CD38\",\n      \"target\": \"NAD+\",\n      \"relationship\": \"major_consumer_aging\",\n      \"pmid\": \"30241982\",\n      \"context\": \"CD38 larger consumer than PARP1 in aging immune cells\"\n    },\n    {\n      \"source\": \"NAMPT\",\n      \"target\": \"SIRT1\",\n      \"relationship\": \"provides_substrate\",\n      \"pmid\": null,\n      \"context\": \"NAD+ salvage axis\"\n    },\n    {\n      \"source\": \"LDHB\",\n      \"target\": \"PVALB\",\n      \"relationship\": \"enriched_in_interneurons\",\n      \"pmid\": \"28602351\",\n      \"context\": \"Human PV basket cells preferentially express LDHB\"\n    },\n    {\n      \"source\": \"MCT1\",\n      \"target\": \"LDHB\",\n      \"relationship\": \"lactate_transport\",\n      \"pmid\": \"20870729\",\n      \"context\": \"Astrocytic lactate export to neurons\"\n    },\n    {\n      \"source\": \"MCT1\",\n      \"target\": \"SLC16A1\",\n      \"relationship\": \"same_gene\",\n      \"pmid\": null,\n      \"context\": \"Alias relationship\"\n    },\n    {\n      \"source\": \"ESRRA\",\n      \"target\": \"PGC-1α\",\n      \"relationship\": \"coactivated_by\",\n      \"pmid\": \"14651853\",\n      \"context\": \"ERRα regulated by PGC-1α for mitochondrial biogenesis\"\n    },\n    {\n      \"source\": \"C3\",\n      \"target\": \"PVALB\",\n      \"relationship\": \"prunes_synapses\",\n      \"pmid\": \"30643258\",\n      \"context\": \"C1q/C3-dependent synaptic pruning at PV perisomatic synapses\"\n    },\n    {\n      \"source\": \"C1Q\",\n      \"target\": \"C3\",\n      \"relationship\": \"initiates_cascade\",\n      \"pmid\": \"28602351\",\n      \"context\": \"Complement-mediated synapse loss\"\n    },\n    {\n      \"source\": \"SLC7A11\",\n      \"target\": \"Glutathione\",\n      \"relationship\": \"provides_cystine_for\",\n      \"pmid\": \"25280565\",\n      \"context\": \"System xc- provides cystine for GSH synthesis\"\n    },\n    {\n      \"source\": \"SLC7A11\",\n      \"target\": \"Glutamate\",\n      \"relationship\": \"exports\",\n      \"pmid\": null,\n      \"context\": \"xCT antiporter exports glutamate, complicating therapeutic logic\"\n    },\n    {\n      \"source\": \"Alzheimer's Disease\",\n      \"target\": \"ID2\",\n      \"relationship\": \"upregulates_in_prefrontal_cortex\",\n      \"pmid\": \"29668080\",\n      \"context\": \"ID2 significantly elevated in AD\"\n    },\n    {\n      \"source\": \"Ketogenic Diet\",\n      \"target\": \"LDHB\",\n      \"relationship\": \"increases_expression\",\n      \"pmid\": \"29396894\",\n      \"context\": \"In hippocampus\"\n    }\n  ],\n  \"synthesis_summary\": {\n    \"top_3_hypotheses\": [\n      {\n        \"rank\": 1,\n        \"hypothesis_id\": \"H3_PARP1_NAD_depletion\",\n        \"target\": \"PARP1\",\n        \"rationale\": \"Highest composite score (6.18) with strong mechanistic plausibility, existing pharmacological tools, and clear path to validation. Expert confirms PARP1 as one of the most tractable targets with mature structural understanding and FDA-approved inhibitors. Main uncertainty is whether CD38 compensation undermines monotherapy - must be addressed experimentally. Niraparib has best CNS penetration for repurposing attempt.\"\n      },\n      {\n        \"rank\": 2,\n        \"hypothesis_id\": \"H6_Complement_C3_redirect\",\n        \"target\": \"C3/CR3\",\n        \"rationale\": \"Second highest score (5.90) with high druggability and established complement biology. Key advantage: Annexon's C1q program (ANX-005) provides regulatory pathway precedent. Critical concern: stage-dependency of C3 roles (beneficial plaque clearance vs harmful synapse pruning) requires careful experimental design. Must develop CNS-penetrant antibody or C3aR agonist to test 'redirect' hypothesis specifically.\"\n      },\n      {\n        \"rank\": 3,\n        \"hypothesis_id\": \"H2_LDHB_lactate_oxidation\",\n        \"target\": \"LDHB\",\n        \"rationale\": \"Third highest score (5.18) with solid human PV interneuron data and mechanistic novelty. However, mechanistic plausibility reduced by contested lactate shuttle hypothesis and lack of LDHB activators. If metabolic support for PV neurons becomes priority after NAD+ axis is addressed, this should be prioritized with 13C flux studies to determine whether lactate vs glucose is the dominant substrate.\"\n      }\n    ],\n    \"cross-cutting_themes\": [\n      \"PV interneuron metabolic vulnerability emerges as a convergent theme across hypotheses 1, 2, 4, and 5\",\n      \"NAD+ homeostasis (PARP1/CD38/NAMPT/SIRT1 axis) represents a tractable node for intervention\",\n      \"Complement biology requires precise temporal and spatial targeting to avoid harming plaque clearance\",\n      \"Cell-type specificity is a major challenge - most transporters/enzymes are not cell-type selective\",\n      \"BBB penetration remains a significant barrier for biologics-based approaches\"\n    ],\n    \"discarded_hypotheses\": [\n      {\n        \"hypothesis_id\": \"H5_ERRa_agonism\",\n        \"rationale\": \"Cited chemical tool (GSK4716) is ERRβ/γ agonist not ERRα agonist. No selective ERRα agonists exist. Pharmacological dead zone.\"\n      },\n      {\n        \"hypothesis_id\": \"H1_ID2_PV_repression\",\n        \"rationale\": \"Developmental evidence does not translate to adult AD. No chemical matter (transcription factor). No selective ID2 inhibitors or PROTACs. Cell-type specificity unproven.\"\n      },\n      {\n        \"hypothesis_id\": \"H7_xCT_antiporter\",\n        \"rationale\": \"Internal contradiction: xCT activation increases glutamate release while attempting to reduce excitotoxicity. Sulfasalazine effects attributed to NMDA antagonism, not xCT.\"\n      }\n    ],\n    \"recommended_actionable_next_steps\": [\n      \"1. Test niraparib (best CNS PARP inhibitor) at sub-toxic doses in AD models with microglial NAD+, NAMPT flux, and SASP readouts\",\n      \"2. Develop CNS-penetrant anti-C3 or C3aR agonist to test synapse protection vs plaque clearance tradeoffs\",\n      \"3. Conduct 13C-lactate vs 13C-glucose flux tracing with PV-specific LDHB manipulation to resolve lactate shuttle controversy\",\n      \"4. Use NAC as low-cost oxidative stress control to determine if xCT/GSH axis is worth further investment\",\n      \"5. Establish ERRα-selective agonist before pursuing mitochondrial biogenesis hypothesis\"\n    ],\n    \"integrated_confidence_ranking\": [\n      {\"rank\": 1, \"hypothesis\": \"PARP1\", \"confidence\": 0.55},\n      {\"rank\": 2, \"hypothesis\": \"C3 complement\", \"confidence\": 0.48},\n      {\"rank\": 3, \"hypothesis\": \"LDHB\", \"confidence\": 0.38},\n      {\"rank",
  "tokens_used": "5621",
  "persona_id": "persona-synthesizer"
}